Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ProBioGen, Zag Bio Partner to Accelerate Thymus-Targeted Bifunctional Antibody Program | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

ProBioGen, Zag Bio Partner to Accelerate Thymus-Targeted Bifunctional Antibody Program

ProBioGen to provide cell line development, process development, and GMP manufacturing for Zag Bio's lead ZAG-101 product candidate.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

ProBioGen has signed a Master Service Agreement (MSA) with Zag Bio Inc., a biotechnology company developing thymus-targeted therapies to induce central immune tolerance.

Under the MSA’s first integrated service package, ProBioGen will provide cell line development, process development, and GMP manufacturing for Zag Bio’s lead ZAG-101 product candidate for the prevention or delay of Type 1 diabetes, targeted to enter clinical development in the second half of 2026.

“This agreement is more than a contractual milestone. It marks the beginning of a collaborative effort to bring Zag Bio’s highly innovative thymus-targeted bifunctional antibody program to life,” said Dr. Alfred Merz, CEO, ProBioGen. “Our integrated platform combines cutting-edge technologies, harmonized automated workflows, and cross-functional expertise, across development and manufacturing, to accelerate our partner’s biologics programs with precision and flexibility.”

“We chose ProBioGen not just for their scientific excellence, but for their reputation as a truly collaborative and flexible partner,” added Jason Cole, CEO, Zag Bio, “They  impressed us with their deep understanding and integrated capabilities in Fc-fusion protein development, which will enable the manufacturing and clinical development of our lead ZAG-101 molecule, to potentially  deliver transformative impact to patients with Type 1 diabetes and over time, additional autoimmune diseases.”

Financial details of the agreement were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics